Want to stay up to date?
Subscribe to our RSS feeds.
Dr. Robert L. Coleman Named an OncLive® Giant of Cancer Care
Chief Scientific Officer of US Oncology Research honored for groundbreaking achievements in gynecologic oncology
THE WOODLANDS, Texas, Oct. 6, 2020 — Robert L. Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, has been named an inductee to the 2020 class of the OncLive® Giants of Cancer Care®. Now in its eighth year, Giants of Cancer Care is a recognition program celebrating individuals whose achievements have propelled global oncology forward and made remarkable differences in patient care and research. In a virtual ceremony on November 5, Dr. Coleman will receive the award for Gynecological Malignancies, recognizing his many achievements which have established the building blocks for future advancement in the field.
“The members of the 2020 class of Giants of Cancer Care are oncology legends who have made remarkable differences in the cancer care landscape,” said Mike Hennessy, Jr., president and CEO of MJH Life Sciences™, the parent company of OncLive — a multimedia platform connecting healthcare professionals to the latest in oncology advancements, news and resources. Out of 818 nominations, only 15 oncologists were selected as inductees to the 2020 Giants of Cancer Care for their achievements in specialties spanning the field, from breast cancer and melanoma to cancer diagnostics and translational science.
An internationally recognized leader in ovarian, uterine and cervical cancer research, Dr. Coleman has played a key role in developing some of the most promising treatments available today for gynecological cancer management. “I couldn’t be prouder to see Dr. Coleman take his place among the Giants of Cancer Care, a recognition that honors his extraordinary contributions to clinical research in gynecological malignancies,” said Michael Seiden, MD, PhD, president of The US Oncology Network. “His work exploring the role of novel therapies such as PARP inhibitors for ovarian cancer, as well as surgical approaches to ovarian cancer management, continues to make an impact in the lives of patients.”
Dr. Coleman joined The US Oncology Network (The Network) in March 2020, named as chief scientific officer and leader of US Oncology Research, The Network’s clinical research arm. The US Oncology Network, which is supported by McKesson Corporation, is one of the nation’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. “Being inducted into the OncLive Giants of Cancer Care is a great honor, and I’m humbled and inspired to join this group of luminaries in the field of oncology research and care,” Dr. Coleman said. “No cancer researcher works alone, and I’d like to acknowledge and thank the many collaborators working with me to move oncology forward and improve patients’ lives. These are dynamic times for cancer research, and I couldn’t be more excited to continue this critical work with my US Oncology Research colleagues.”
The 8th Annual Giants of Cancer Care virtual awards ceremony will take place on Thursday, November 5, 2020, at 7:30 p.m. EST. It’s free to register for the virtual ceremony, which will be available on demand at giantsofcancercare.com after the conclusion of the event. To learn more about the event and the 2020 class of Giants of Cancer Care, read the OncLive press release.
About US Oncology Research
US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and more than 165 locations, managing about 400 active trials at any given time. For the past 20 years, physicians in the research network have enrolled more than 80,000 patients in over 1,600 trials and have played a role in more than 100 FDA-approved cancer therapies. US Oncology Research is supported by McKesson Corporation.
US Oncology Research